Chipscreen Biosciences, Ltd.
Chipscreen Biosciences, Ltd.
Explore linked clinical trials.15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-06-03 | NCT07303803 | |
| A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-small cell lung carcinoma, pancreatic adenocarcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 1 | 2026-05-13 | NCT07583771 | |
| Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Not stated | 2026-05-12 | NCT07580638 | |
| Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 1 | 2026-04-06 | NCT07511010 | |
| A Study of CS23546 in Subjects With Advanced Tumors | Advanced Tumors | Recruiting | Phase 1 | 2026-04-06 | NCT06245122 | |
| A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-03-19 | NCT06497985 | |
| Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Active, not recruiting | Phase 2 | 2026-03-18 | NCT06492915 | |
| Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Not yet recruiting | Phase 3 | 2026-03-03 | NCT07445295 | |
| Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Recruiting | Phase 3 | 2025-09-15 | NCT06947967 | |
| A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Recruiting | Phase 1 / Phase 2 | 2025-09-10 | NCT07129382 | |
| Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thoracic Neoplasms, astrocytoma (excluding glioblastoma), bronchial neoplasm, bronchogenic carcinoma, epithelial neoplasm, glioblastoma, glioma, lung disorder, lung neoplasm, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 1 | 2025-05-25 | NCT06902350 | |
| VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2025-02-19 | NCT05603884 | |
| Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer | Adnexal Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2024-10-18 | NCT04921527 | |
| A Study of NWY001 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2024-07-16 | NCT05979155 | |
| A Study of Chidamide With AZA in MRD Positive AML After Transplant | Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not applicable | 2023-10-27 | NCT06066905 |